210 related articles for article (PubMed ID: 37342059)
1. Amid Paraguay Chikungunya Outbreak, Vaccine Candidate Safe, Immunogenic.
Harris E
JAMA; 2023 Jul; 330(2):111. PubMed ID: 37342059
[No Abstract] [Full Text] [Related]
2. Development of Vaccines for Chikungunya Fever.
Erasmus JH; Rossi SL; Weaver SC
J Infect Dis; 2016 Dec; 214(suppl 5):S488-S496. PubMed ID: 27920179
[TBL] [Abstract][Full Text] [Related]
3. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE
J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180
[TBL] [Abstract][Full Text] [Related]
4. Do we need a vaccine against chikungunya?
Rezza G
Pathog Glob Health; 2015 Jun; 109(4):170-3. PubMed ID: 25971340
[TBL] [Abstract][Full Text] [Related]
5. A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.
Folegatti PM; Harrison K; Preciado-Llanes L; Lopez FR; Bittaye M; Kim YC; Flaxman A; Bellamy D; Makinson R; Sheridan J; Azar SR; Campos RK; Tilley M; Tran N; Jenkin D; Poulton I; Lawrie A; Roberts R; Berrie E; Rossi SL; Hill A; Ewer KJ; Reyes-Sandoval A
Nat Commun; 2021 Jul; 12(1):4636. PubMed ID: 34330906
[TBL] [Abstract][Full Text] [Related]
6. Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.
Eldi P; Cooper TH; Liu L; Prow NA; Diener KR; Howley PM; Suhrbier A; Hayball JD
Mol Ther; 2017 Oct; 25(10):2332-2344. PubMed ID: 28720468
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
Ramsauer K; Schwameis M; Firbas C; Müllner M; Putnak RJ; Thomas SJ; Desprès P; Tauber E; Jilma B; Tangy F
Lancet Infect Dis; 2015 May; 15(5):519-27. PubMed ID: 25739878
[TBL] [Abstract][Full Text] [Related]
8. Recent development in the strategies projected for chikungunya vaccine in humans.
Goyal M; Chauhan A; Goyal V; Jaiswal N; Singh S; Singh M
Drug Des Devel Ther; 2018; 12():4195-4206. PubMed ID: 30573950
[TBL] [Abstract][Full Text] [Related]
9. Defining a correlate of protection for chikungunya virus vaccines.
Milligan GN; Schnierle BS; McAuley AJ; Beasley DWC
Vaccine; 2019 Nov; 37(50):7427-7436. PubMed ID: 30448337
[TBL] [Abstract][Full Text] [Related]
10. Chikungunya Virus Vaccines: Viral Vector-Based Approaches.
Ramsauer K; Tangy F
J Infect Dis; 2016 Dec; 214(suppl 5):S500-S505. PubMed ID: 27920181
[TBL] [Abstract][Full Text] [Related]
11. Therapeutics and vaccines against chikungunya virus.
Ahola T; Couderc T; Ng LF; Hallengärd D; Powers A; Lecuit M; Esteban M; Merits A; Roques P; Liljeström P
Vector Borne Zoonotic Dis; 2015 Apr; 15(4):250-7. PubMed ID: 25897811
[TBL] [Abstract][Full Text] [Related]
12. A chikungunya fever vaccine utilizing an insect-specific virus platform.
Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC
Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917
[TBL] [Abstract][Full Text] [Related]
13. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.
Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W
Front Immunol; 2021; 12():655743. PubMed ID: 33868299
[TBL] [Abstract][Full Text] [Related]
14. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.
Roques P; Ljungberg K; Kümmerer BM; Gosse L; Dereuddre-Bosquet N; Tchitchek N; Hallengärd D; García-Arriaza J; Meinke A; Esteban M; Merits A; Le Grand R; Liljeström P
JCI Insight; 2017 Mar; 2(6):e83527. PubMed ID: 28352649
[TBL] [Abstract][Full Text] [Related]
15. Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.
Kam YW; Lee WW; Simarmata D; Le Grand R; Tolou H; Merits A; Roques P; Ng LF
PLoS One; 2014; 9(4):e95647. PubMed ID: 24755730
[TBL] [Abstract][Full Text] [Related]
16. An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses.
Ge N; Sun J; Liu Z; Shu J; Yan H; Kou Z; Wei Y; Jin X
Virol Sin; 2022 Apr; 37(2):266-276. PubMed ID: 35527225
[TBL] [Abstract][Full Text] [Related]
17. Chikungunya: out of the tropical forests and heading our way ….
Rowland-Jones SL
Trans R Soc Trop Med Hyg; 2016 Feb; 110(2):85-6. PubMed ID: 26822599
[No Abstract] [Full Text] [Related]
18. Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus.
Yang S; Fink D; Hulse A; Pratt RD
Vaccine; 2017 Sep; 35(37):4851-4858. PubMed ID: 28760614
[TBL] [Abstract][Full Text] [Related]
19. Chikungunya Outbreaks in India: A Prospective Study Comparing Neutralization and Sequelae during Two Outbreaks in 2010 and 2016.
Jain J; Kaur N; Haller SL; Kumar A; Rossi SL; Narayanan V; Kumar D; Gaind R; Weaver SC; Auguste AJ; Sunil S
Am J Trop Med Hyg; 2020 Apr; 102(4):857-868. PubMed ID: 32067624
[TBL] [Abstract][Full Text] [Related]
20. Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.
van den Doel P; Volz A; Roose JM; Sewbalaksing VD; Pijlman GP; van Middelkoop I; Duiverman V; van de Wetering E; Sutter G; Osterhaus AD; Martina BE
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3101. PubMed ID: 25188230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
